Literature DB >> 8667462

Five year retrospective evaluation of sulfonylurea ingestion in children.

D A Quadrani1, H A Spiller, P Widder.   

Abstract

BACKGROUND: Oral hypoglycemic medications are frequently used for Type II diabetes and accidental ingestions by children may occur. There are no comprehensive pediatric studies documenting poison center experiences. STUDY
OBJECTIVE: To evaluate the toxicity of oral sulfonylurea ingestion in children and the efficacy of treatments instituted in these cases.
METHOD: Retrospective review of all ingestions of oral sulfonylureas reported to a single regional poison control center 1987-1991.
RESULTS: Ninety-three cases were identified, one to 16 years old (mean of 3.5 years). Eighty cases (86%) were less than six years of age. Of the six medications used, three, chlorpropamide, glipizide and glyburide made up 88 (95%) cases. Twenty-five patients (27%) became hypoglycemic (glucose < 60 mg/dL). The mean minimum blood glucose in these patients was 46.5 mg/dL (minimum 20 mg/dL). Time of onset of hypoglycemia ranged from 0.5 to 16 h (mean 4.3 h; median 2 h). Only four patients had the onset of chemical hypoglycemia more than four hours postexposure. Persistent hypoglycemia occurred in nine children (10%) despite intravenous glucose therapy. There were no seizures. Mean time to decontamination of patients with and without hypoglycemia was 1.4 and 1.2 h respectively. Intravenous glucose of the following concentrations was administered: 5% (40), 10% (15), 20% (1), and 50% (3). Accidental ingestion of a single tablet of chlorpropamide (250 mg), glipizide (5 mg). and glyburide (2.5 mg) each produced hypoglycemia in children ages one to four years. Accidental ingestion of 5-10 mg glyburide produced a blood glucose of 57 mg/dL in an 11-year-old child. All patients recovered fully. There were no neurological sequelae noted.
CONCLUSION: Children ingesting oral hypoglycemics should be admitted to a health care facility for 24 h observation. In this series a single tablet produced hypoglycemia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8667462     DOI: 10.3109/15563659609013787

Source DB:  PubMed          Journal:  J Toxicol Clin Toxicol        ISSN: 0731-3810


  9 in total

Review 1.  Poisoning in children 5: rare and dangerous poisons.

Authors:  M Riordan; G Rylance; K Berry
Journal:  Arch Dis Child       Date:  2002-11       Impact factor: 3.791

2.  Unwitnessed sulphonylurea poisoning in a healthy toddler.

Authors:  Pei Ying Loo; Fabian Yap
Journal:  Eur J Pediatr       Date:  2010-05-15       Impact factor: 3.183

3.  Case files of the Medical Toxicology Fellowship Training Program at the Children's Hospital of Philadelphia: a pediatric exploratory sulfonylurea ingestion.

Authors:  Diane P Calello; Andrea Kelly; Kevin C Osterhoudt
Journal:  J Med Toxicol       Date:  2006-03

Review 4.  Octreotide's role in the management of sulfonylurea-induced hypoglycemia.

Authors:  Patrick P Dougherty; Wendy Klein-Schwartz
Journal:  J Med Toxicol       Date:  2010-06

5.  Toxicology case of the month: ingestion of two unidentified tablets by a toddler.

Authors:  D McCoubrie; L Murray; F F S Daly; M Little
Journal:  Emerg Med J       Date:  2006-09       Impact factor: 2.740

Review 6.  Kir6.1 and SUR2B in Cantú syndrome.

Authors:  Conor McClenaghan; Colin G Nichols
Journal:  Am J Physiol Cell Physiol       Date:  2022-07-25       Impact factor: 5.282

Review 7.  Management of antidiabetic medications in overdose.

Authors:  H A Spiller
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

8.  Extended-release glipizide overdose presenting with delayed hypoglycemia and treated with subcutaneous octreotide.

Authors:  Paul I Pelavin; Erika Abramson; Steven Pon; Maria G Vogiatzi
Journal:  J Pediatr Endocrinol Metab       Date:  2009-02       Impact factor: 1.634

Review 9.  Treatment of sulfonylurea and insulin overdose.

Authors:  Wendy Klein-Schwartz; Gina L Stassinos; Geoffrey K Isbister
Journal:  Br J Clin Pharmacol       Date:  2016-01-06       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.